6-ECDCA-d4 (Synonyms: 6α-ethyl Chenodeoxycholic Acid-d4,Obeticholic Acid-d4) |
| カタログ番号GC91564 |
6-ECDCA-d4 is intended for use as an internal standard for the quantification of 6-ECDCA by GC- or LC-MS.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2025364-15-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
6-ECDCA-d4 is intended for use as an internal standard for the quantification of 6-ECDCA by GC- or LC-MS. 6-ECDCA is a synthetic bile acid that acts as a potent and selective agonist of the farnesoid X receptor (FXR; EC50 = 99 nM).[1] Through FXR, it alters gene expression that results in protection against cholestasis, as well as liver fibrosis, in animal models.1,2,3 6-ECDCA also, through FXR, promotes the differentiation of adipocytes and enhances insulin signaling in mature adipocytes.[4] In ApoE-/- mice, 6-ECDCA ameliorates vascular calcification secondary to chronic kidney disease without affecting the development of atherosclerosis.[5]
References:
[1].Pellicciari, R., Fiorucci, S., Camaioni, E., et al.6α-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activityJ. Med. Chem.45(17)3569-3572(2002).
[2].Fiorucci, S., Clerici, C., Antonelli, E., et al.Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasisJ. Pharmacol. Exp. Ther.313(2)604-612(2005).
[3].Fiorucci, S., Rizzo, G., Antonelli, E., et al.A farnesoid X receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosisJ. Pharmacol. Exp. Ther.314(2)584-595(2005).
[4].Rizzo, G., Disante, M., Mencarelli, A., et al.The farnesoid X receptor promotes adipocyte differentiation and regulates adipose cell function in vivoMol. Pharmacol.70(4)1164-1173(2006).
[5].Miyazaki-Anzai, S., Levi, M., Kratzer, A., et al.Farnesoid X receptor activation prevents the development of vascular calcification in ApoE-/- mice with chronic kidney diseaseCirc. Res.106(12)1807-1817(2010).
| Cas No. | 2025364-15-0 | SDF | |
| 同義語 | 6α-ethyl Chenodeoxycholic Acid-d4,Obeticholic Acid-d4 | ||
| Formula | C26H40D4O4 | M.Wt | 424.7 |
| 溶解度 | DMSO: Sparingly Soluble: 1-10 mg/ml,Ethanol: Sparingly Soluble: 1-10 mg/ml | Storage | -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.3546 mL | 11.773 mL | 23.546 mL |
| 5 mM | 0.4709 mL | 2.3546 mL | 4.7092 mL |
| 10 mM | 0.2355 mL | 1.1773 mL | 2.3546 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *